Skip to search formSkip to main contentSkip to account menu

DX 8951f

Known as: DX-8951f 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity… 
2004
2004
Background: To evaluate the antitumor activity, toxicities, and pharmacokinetics (PK) of DX-8951f administered as a 30-min… 
2004
2004
Purpose: Many promising anticancer drugs are limited by myelosuppression. It is difficult to evaluate human myelotoxicity before… 
Highly Cited
2003
Highly Cited
2003
We determined the antitumor and antimetastatic efficacy of the camptothecin analogue DX-8951f in an orthotopic metastatic mouse… 
2003
2003
PURPOSE 9-Aminocamptothecin colloidal dispersion (9-ACCD; NSC 603071) is a specific inhibitor of topoisomerase I that can be… 
2002
2002
The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin), also known as Karenitecin, has been… 
2000
2000
PURPOSE DX-8951f is a totally synthetic derivative of camptothecin with greater cytotoxicity and more potent topoisomerase I… 
1998
1998
DX‐8951f, a water‐soluble and non‐pro‐drug analogue of camptothecin, exhibits a strong inhibitory action on DNA topoisomerase I… 
Highly Cited
1997
Highly Cited
1997
We previously reported that DX‐8951f, a novel water‐soluble camptothecin analog, significantly inhibits the growth of various…